LS Investment Advisors’s Usana Health Sciences USNA Stock Holding History

LS Investment Advisors’s Portfolio USNA Stock Details USNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-398	Closed	-$29K	–	1431
2020 Q2	$29K	Hold	398	–	–	﹤0.01%	1307
2020 Q1	$23K	Hold	398	–	–	﹤0.01%	1325
2019 Q4	$31K	Hold	398	–	–	﹤0.01%	1439
2019 Q3	$27K	Hold	398	–	–	﹤0.01%	1465
2019 Q2	$32K	Buy	+398	New	+$31.6K	﹤0.01%	1425

Other funds holding USNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LS Investment Advisors's USNA Position: Q3 2020 in Review

LS Investment Advisors sold out of Usana Health Sciences (USNA) in Q3 2020, closing a stake of 398 shares — an estimated $29K sold.

LS Investment Advisors first reported a position in USNA in Q2 2019 and held it in 5 quarters. The position peaked at $32K in Q2 2019. 192 funds tracked by Wall St. Rank hold USNA as of Q3 2020.

LS Investment Advisors reported no remaining Usana Health Sciences position as of Q3 2020 after selling out during the quarter.
LS Investment Advisors sold 398 Usana Health Sciences shares in Q3 2020, an estimated $29K.
LS Investment Advisors first reported a position in Usana Health Sciences in Q2 2019 and held it in 5 quarters.
LS Investment Advisors's Usana Health Sciences position peaked at $32K in Q2 2019.
192 funds tracked by Wall St. Rank held Usana Health Sciences as of Q3 2020.

Based on LS Investment Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.